Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 9

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Structural Studies on Mechanisms to Activate Mutant p53

Viadiu, Hector, Fronza, Gilberto, Inga, Alberto·2014·Subcellular Biochemistry
DOI 10.1007/978-94-017-9211-0_7
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/978-94-017-9211-0_7

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Research works printed but not linked: 56

  1. Aguilar F, Hussain SP, Cerutti P (1993) Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci U S A 90:8586–8590 · DOI · Paper page
  2. Aramayo R, Sherman MB, Brownless K, Lurz R, Okorokov AL, Orlova EV (2011) Quaternary structure of the specific p53-DNA complex reveals the mechanism of p53 mutant dominance. Nucleic Acids Res 39:8960–8971 · DOI · Paper page
  3. Arbely E, Natan E, Brandt T, Allen MD, Veprintsev DB, Robinson CV, Chin JW, Joerger AC, Fersht AR (2011) Acetylation of lysine 120 of p53 endows DNA-binding specificity at effective physiological salt concentration. Proc Natl Acad Sci U S A 108:8251–8256 · DOI
  4. Baroni TE, Wang T, Qian H, Dearth LR, Truong LN, Zeng J, Denes AE, Chen SW, Brachmann RK (2004) A global suppressor motif for p53 cancer mutants. Proc Natl Acad Sci USA 101:4930–4935 · DOI
  5. Basse N, Kaar JL, Settanni G, Joerger AC, Rutherford TJ, Fersht AR (2010) Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. Chem Biol 17:46–56 · DOI · Paper page
  6. Bassett EA, Wang W, Rastinejad F, El-Deiry WS (2008) Structural and functional basis for therapeutic modulation of p53 signaling. Clin Cancer Res 14:6376–6386 · DOI
  7. Boeckler FM, Joerger AC, Jaggi G, Rutherford TJ, Veprintsev DB, Fersht AR (2008) Targeted rescue of a destabilized mutant of p53 by an in silico screened drug. Proc Natl Acad Sci U S A 105:10360–10365 · DOI · Paper page
  8. Brachmann RK, Yu K, Eby Y, Pavletich NP, Boeke JD (1998) Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. EMBO J 17:1847–1859 · DOI · Paper page
  9. Brown CJ, Cheok CF, Verma CS, Lane DP (2011) Reactivation of p53: from peptides to small molecules. Trends Pharmacol Sci 32:53–62 · DOI
  10. Chen Y, Dey R, Chen L (2010) Crystal structure of the p53 core domain bound to a full consensus site as a self-assembled tetramer. Structure 18:246–256 · DOI · Paper page
  11. Chen Y, Zhang X, Dantas Machado AC, Ding Y, Chen Z, Qin PZ, Rohs R, Chen L (2013) Structure of p53 binding to the BAX response element reveals DNA unwinding and compression to accommodate base-pair insertion. Nucleic Acids Res 41:8368–8376 · DOI · Paper page
  12. Ciribilli Y, Monti P, Bisio A, Nguyen HT, Ramos A, Ethayathulla AS, Foggetti G, Menichini P, Menendez D, Resnick MA, Viadiu H, Fronza G, Inga A (2013) Transactivation specificity is conserved among p53 family proteins and depends on a response element sequence code. Nucleic Acids Res 41:8637–8653 · DOI
  13. Coffill CR, Muller PAJ, Oh HK, Neo SP, Hogue KA, Cheok CF, Vousden KH, Lane DP, Blackstock WP, Gunaratne J (2012) Mutant p53 interactome identifies nardilysin as a p53R273H-specific binding partner that promotes invasion. EMBO Rep 13:638–644 · DOI
  14. Davison TS, Nie X, Ma W, Lin Y, Kay C, Benchimol S, Arrowsmith CH (2001) Structure and functionality of a designed p53 dimer. J Mol Biol 307:605–617 · DOI
  15. Davison TS, Yin P, Nie E, Kay C, Arrowsmith CH (1998) Characterization of the oligomerization defects of two p53 mutants found in families with Li-Fraumeni and Li-Fraumeni-like syndrome. Oncogene 17:651–656 · DOI
  16. Emamzadah S, Tropia L, Halazonetis TD (2011) Crystal structure of a multidomain human p53 tetramer bound to the natural CDKN1A (p21) p53-response element. Mol Cancer Res 9:1493–1499 · DOI
  17. Espinosa JM (2008) Mechanisms of regulatory diversity within the p53 transcriptional network. Oncogene 27:4013–4023 · DOI
  18. Ethayathulla AS, Nguyen HT, Viadiu H (2013) Crystal structures of the DNA-binding domain tetramer of the p53 tumor suppressor family member p73 bound to different full-site response elements. J Biol Chem 288:4744–4754 · DOI
  19. Ethayathulla AS, Tse P-W, Monti P, Nguyen S, Inga A, Fronza G, Viadiu H (2012) Structure of p73 DNA-binding domain tetramer modulates p73 transactivation. Proc Natl Acad Sci U S A 109:6066–6071 · DOI
  20. Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286:2507–2510 · DOI · Paper page
  21. Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26:1268–1286 · DOI · Paper page
  22. Ho WC, Fitzgerald MX, Marmorstein R (2006) Structure of the p53 core domain dimer bound to DNA. J Biol Chem 281:20494–20502 · DOI · Paper page
  23. Inga A, Monti P, Fronza G, Darden T, Resnick MA (2001) p53 mutants exhibiting enhanced transcriptional activation and altered promoter selectivity are revealed using a sensitive, yeast-based functional assay. Oncogene 20:501–513 · DOI
  24. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61:69–90 · DOI · Paper page
  25. Joerger AC, Fersht AR (2010) The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2:a000919 · DOI · Paper page
  26. Joerger AC, Fersht AR (2008) Structural biology of the tumor suppressor p53. Annu Rev Biochem 77:557–582 · DOI · Paper page
  27. Joerger AC, Allen MD, Fersht AR (2004) Crystal structure of a superstable mutant of human p53 core domain. Insights into the mechanism of rescuing oncogenic mutations. J Biol Chem 279:1291–1296 · DOI · Paper page
  28. Joerger AC, Ang HC, Fersht AR (2006) Structural basis for understanding oncogenic p53 mutations and designing rescue drugs. Proc Natl Acad Sci U S A 103:15056–15061 · DOI · Paper page
  29. Joerger AC, Ang HC, Veprintsev DB, Blair CM, Fersht AR (2005) Structures of p53 cancer mutants and mechanism of rescue by second-site suppressor mutations. J Biol Chem 280:16030–16037 · DOI · Paper page
  30. Kato S, Han S-Y, Liu W, Otsuka K, Shibata H, Kanamaru R, Ishioka C (2003) Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis. Proc Natl Acad Sci U S A 100:8424–8429 · DOI · Paper page
  31. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, Shakked Z (2006) Structural basis of DNA recognition by p53 tetramers. Mol Cell 22:741–753 · DOI · Paper page
  32. Kitayner M, Rozenberg H, Rohs R, Suad O, Rabinovich D, Honig B, Shakked Z (2010) Diversity in DNA recognition by p53 revealed by crystal structures with Hoogsteen base pairs. Nat Struct Mol Biol 17:423–429 · DOI · Paper page
  33. Leroy B, Fournier JL, Ishioka C, Monti P, Inga A, Fronza G, Soussi T (2013) The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis. Nucleic Acids Res 41:D962–D969 · DOI · Paper page
  34. Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41:6034–6044 · DOI · Paper page
  35. Malecka KA, Ho WC, Marmorstein R (2009) Crystal structure of a p53 core tetramer bound to DNA. Oncogene 28:325–333 · DOI
  36. Melero R, Rajagopalan S, Lázaro M, Joerger AC, Brandt T, Veprintsev DB, Lasso G, Gil D, Scheres SHW, Carazo JM et al (2011) Electron microscopy studies on the quaternary structure of p53 reveal different binding modes for p53 tetramers in complex with DNA. Proc Natl Acad Sci U S A 108:557–562 · DOI · Paper page
  37. Mora P, Carbajo RJ, Pineda-Lucena A, Sánchez del Pino MM, Pérez-Payá E (2008) Solvent-exposed residues located in the beta-sheet modulate the stability of the tetramerization domain of p53 – a structural and combinatorial approach. Proteins 71:1670–1685 · DOI
  38. Nikolova PV, Wong KB, DeDecker B, Henckel J, Fersht AR (2000) Mechanism of rescue of common p53 cancer mutations by second-site suppressor mutations. EMBO J 19:370–378 · DOI · Paper page
  39. Okorokov AL, Orlova EV (2009) Structural biology of the p53 tumour suppressor. Curr Opin Struct Biol 19:197–202 · DOI
  40. Olivier M, Goldgar DE, Sodha N, Ohgaki H, Kleihues P, Hainaut P, Eeles RA (2003) Li-Fraumeni and related syndromes. Cancer Res 63:6643–6650
  41. Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2:a001107 · DOI · Paper page
  42. Otsuka K, Kato S, Kakudo Y, Mashiko S, Shibata H, Ishioka C (2007) The screening of the second-site suppressor mutations of the common p53 mutants. Int J Cancer 121:559–566 · DOI · Paper page
  43. Petty TJ, Emamzadah S, Costantino L, Petkova I, Stavridi ES, Saven JG, Vauthey E, Halazonetis TD (2011) An induced fit mechanism regulates p53 DNA binding kinetics to confer sequence specificity. EMBO J 30:2167–2176 · DOI · Paper page
  44. Pham N, Lucumi A, Cheung N, Viadiu H (2012) The tetramer of p53 in the absence of DNA forms a relaxed quaternary state. Biochemistry 51:8053–8055 · DOI
  45. Razzak M (2013) Targeted therapies: one step closer to drugging p53. Nat Rev Clin Oncol 10:246 · doi:10.1038/nrclinonc.2013.43
  46. Rees DC, Congreve M, Murray CW, Carr R (2004) Fragment-based lead discovery. Nat Rev Drug Discov 3:660–672 · DOI · Paper page
  47. Resnick MA, Inga A (2003) Functional mutants of the sequence-specific transcription factor p53 and implications for master genes of diversity. Proc Natl Acad Sci U S A 100:9934–9939 · DOI · Paper page
  48. Rippin TM, Bykov VJN, Freund SMV, Selivanova G, Wiman KG, Fersht AR (2002) Characterization of the p53-rescue drug CP-31398 in vitro and in living cells. Oncogene 21:2119–2129 · DOI · Paper page
  49. Selivanova G (2010) Therapeutic targeting of p53 by small molecules. Semin Cancer Biol 20:46–56 · DOI
  50. Suad O, Rozenberg H, Brosh R, Diskin-Posner Y, Kessler N, Shimon LJW, Frolow F, Liran A, Rotter V, Shakked Z (2009) Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations. J Mol Biol 385:249–265 · DOI · Paper page
  51. Tidow H, Melero R, Mylonas E, Freund SMV, Grossmann JG, Carazo JM, Svergun DI, Valle M, Fersht AR (2007) Quaternary structures of tumor suppressor p53 and a specific p53 DNA complex. Proc Natl Acad Sci U S A 104:12324–12329 · DOI · Paper page
  52. Viadiu H (2008) Molecular architecture of tumor suppressor p53. Curr Top Med Chem 8:1327–1334 · doi:10.2174/156802608786141160
  53. Vousden KH, Lane DP (2007) p53 in health and disease. Nat Rev Mol Cell Biol 8:275–283 · DOI · Paper page
  54. Vousden KH, Prives C (2009) Blinded by the light: the growing complexity of p53. Cell 137:413–431 · DOI · Paper page
  55. Wang Y, Rosengarth A, Luecke H (2007) Structure of the human p53 core domain in the absence of DNA. Acta Crystallogr D Biol Crystallogr 63:276–281 · DOI
  56. Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, Tom E, Mack DH, Levine AJ (2000) Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. Genes Dev 14:981–993 · DOI · Paper page

Cited by

See all 9

Metadata

Authors
Viadiu, H., Fronza, G., & Inga, A.
Venue
Subcellular Biochemistry
Publisher
Springer Netherlands
Published
2014
Pages
119-132
ISSN
0306-0225
DOI
10.1007/978-94-017-9211-0_7
Cited by
9
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Structural Studies on Mechanisms to Activate Mutant p53. https://app.cochat.ai/papers/10.1007/978-94-017-9211-0_7
The paper
Viadiu, H., Fronza, G., & Inga, A. (2014). Structural Studies on Mechanisms to Activate Mutant p53. Subcellular Biochemistry. https://doi.org/10.1007/978-94-017-9211-0_7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.